ASCO Annual Meeting | Conference

Updated Cabozantinib Data Includes 6 Patient Deaths

June 7th 2011

Cabozantinib (XL184), a novel tyrosine kinase inhibitor, caused the deaths of 6 patients in a phase II clinical trial.

Dr. Vogelzang on Mortalities in the Cabozantinib Trial

June 7th 2011

Dr. Vogelzang from the Comprehensive Cancer Centers of Nevada discusses mortalities in cabozantinib trial.

Post-Oophorectomy Hormone Replacement Therapy Safe for BRCA1/2 Mutation Carriers

June 7th 2011

Women who present with BRCA1 and BRCA2 mutation face an increased risk of breast and ovarian cancer.

Dr. Infante Talks About BRAF Mutation Testing

June 7th 2011

Dr. Infante from Sarah Cannon Research Institute Talks About BRAF Mutation Testing

PTEN Expression Does Not Diminish Trastuzumab Effectiveness

June 7th 2011

Phosphatase and tensin homolog (PTEN)-positive breast cancer can be treated with trastuzumab (Herceptin) as effectively as PTEN-negative breast cancer

ASCO 2011 Annual Meeting Picture Slideshow Day Four

June 7th 2011

American Society of Clinical Oncology 2011 Annual Meeting Picture Slideshow Day Four

Axitinib Outperforms Sorafenib in Renal Cell Carcinoma Trial

June 7th 2011

Axitinib demonstrated significantly better progression-free survival (PFS) compared with sorafenib

Deciphering the Challenge of the Genomic Era in Breast Cancer

June 6th 2011

Luminal A genetic signature in node-negative, estrogen receptor- (ER-) positive breast cancer predicts a very high disease-free survival rate

Rethinking Initial Management of Patients With Brain Metastasis and HER2 Breast Cancer

June 6th 2011

Lapatinib and capecitabine is a reasonable approach in a well-informed patient with brain metastasis and HER2+ breast cancer

Two Studies Herald New Era in Melanoma Therapy

June 6th 2011

New treatment approaches that improve overall survival for patients with late-stage melanoma spotlighted

Three-Year Imatinib Regimen Delivers Optimal GIST Treatment

June 6th 2011

3 years of treatment with imatinib (Gleevec) after surgery in patients with high-risk GIST improved overall and recurrence-free survival

Pemetrexed Maintenance Improves Progression-Free Survival in Patients With NSCLC

June 6th 2011

Continuation maintenance with pemetrexed (Alimta) improves progression-free survival in patients with advanced nonsquamous non–small cell lung cancer

Dr. Wolchok Describes the Immunotherapy Ipilimumab

June 6th 2011

Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes the Immunotherapy Ipilimumab

Dr. Kris on the Use of Genetic Testing in Lung Cancer

June 6th 2011

Dr. Kris From Memorial Sloan-Kettering Cancer Center on the Use of Genetic Testing in Lung Cancer

MEK and BRAF Therapy Combo Promising for Advanced Melanoma

June 5th 2011

The combination of the MEK inhibitor GSK212 and the oral BRAF inhibitor GSK436 resulted in anti-tumor activity in patients with advanced melanoma

Dr. Virgo on Survivorship Care Training & Policies

June 5th 2011

Dr. Katherine Virgo from the American Cancer Society Discusses Survivorship Care Training & Policies

Dr. Hoos on the Patients That Respond to Ipilimumab

June 5th 2011

Dr. Axel Hoos from Bristol Myers-Squib on the Patients That Respond to Ipilimumab

Dr. Chapman Describes the Side Effects of Vemurafenib

June 5th 2011

Dr. Paul Chapman from Memorial Sloan-Kettering Cancer Center Describes the Side Effects of Vemurafenib

Dr. Tsimberidou Discusses Improving Care

June 5th 2011

Apostolia M. Tsimberidou, MD, PhD, from MD Anderson Cancer Center discusses improving cancer care.

Dr. Cella on Patient Assessment Reference Scores

June 5th 2011

Dr. Cella from Northwestern University Feinberg School of Medicine on Patient Assessment Reference Scores

NEXT PAGE
PREVIOUS PAGE